Mae Tighe, MD
Gastroenterology · New Haven, CTNPI 1184765844
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,750 of the $39,130 with a category attached, or 91.4%. Salix Pharmaceuticals, A Division Of Bausch Health US, LLC accounts for 95.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $9,193 and has fallen 97.5% since, to $232 in 2025. Among gastroenterology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $621.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$37K
- AbbVie$1K
- Sanofi$155
- Takeda Pharmaceuticals U.S.A., Inc.$125
- Pfizer$123
- Madrigal Pharmaceuticals$117
- plus $161 from 3 others
Across 14 payments — averaging $2171.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Adare Pharmaceuticals, Inc.$30K
What the payments were for
- Speaking & faculty fees$35,75091%
- Travel & lodging$2551%
- Food & beverage$3,1258%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 33 | $37,229 |
| AbbVie(2 entities) | 21 | $1,221 |
| Sanofi | 2 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Pfizer | 1 | $123 |
| Madrigal Pharmaceuticals | 1 | $117 |
| Boston Scientific | 2 | $104 |
| Bristol Myers Squibb | 1 | $30 |
| Ardelyx, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,130 in reported general payments places this provider in the 90th percentile of 326 gastroenterology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 13 | $104,447 |
| CreonLipase/Protease/Amylase | 50 | $76,558 |
| ZenpepLipase/Protease/Amylase | 34 | $71,418 |
| XifaxanRifaximin | 25 | $53,232 |
| LinzessLinaclotide | 58 | $52,047 |
| TrulancePlecanatide | 21 | $31,141 |
| MotegrityPrucalopride Succinate | 20 | $25,034 |
| Dexlansoprazole DrDexlansoprazole | 38 | $12,901 |
| Alosetron Hcl | 29 | $7,056 |
| Mesalamine | 18 | $6,326 |
| Mesalamine ErMesalamine | 13 | $5,026 |
| Famotidine | 233 | $4,610 |
| Lubiprostone | 27 | $4,517 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 25 | $4,348 |
| Pantoprazole Sodium | 220 | $3,774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,221 | $128,605108 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $37,229 | $84,37346 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $125 | $25,03420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 326 gastroenterology providers in Connecticut.
Other gastroenterology in New Haven
- Pramod MistryNew Haven$126K
- Daniel ZanchettiNew Haven$94K
- Pichamol JirapinyoNew Haven$84K
- Jill GaidosNew Haven$69K
- Myron BrandNew Haven$60K
- Harry AslanianNew Haven$52K
- James BoyerNew Haven$48K
- Thiruvengadam MunirajNew Haven$45K
- Badr Al BawardyNew Haven$42K
- Priya JamidarNew Haven$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.